Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy

Michal Laufer-Perl; Moran Perelman-Gvili; Svetlana Sirota Dorfman; Guy Baruch; Ehud Rothschild; Gil Beer; Yaron Arbel; Joshua H. Arnold; Zach Rozenbaum; Shmuel Banai; Yan Topilsky; Livia Kapusta

doi:10.3390/life12020291

Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy

Michal Laufer-Perl^*, Moran Perelman-Gvili^*, Svetlana Sirota Dorfman, Guy Baruch, Ehud Rothschild, Gil Beer, Yaron Arbel, Joshua H. Arnold, Zach Rozenbaum, Shmuel Banai, Yan Topilsky, Livia Kapusta

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: Anthracycline (ANT) is the most recognized therapy known to cause cardi-otoxicity, mainly left ventricle (LV) dysfunction. Global Longitudinal Strain (GLS) is the optimal tool for assessment of subclinical LV dysfunction. Right ventricle (RV) function has been recognized as an independent factor for cardiac outcomes; however, data evaluating RV GLS is limited. We aimed to evaluate the change in RV GLS following ANT therapy. Methods: The study cohort is part of the Israel Cardio-Oncology Registry (ICOR). All patients performed echocardiography before (T1) and at the end (T3) of ANT therapy. A significant reduction was defined as a relative reduction of ≥ 10% in RV GLS values. Results: The study included 40 female patients with breast cancer treated with ANT. During follow-up, both RV GLS and free wall longitudinal strain systolic peak (RV FWLS PK) decreased significantly (p < 0.001 and p = 0.002). Altogether, 30 (75%) and 23 (58%) patients showed RV GLS and RV FWLS PK ≥ 10% relative reduction. At T3, LV ejection fraction and LV GLS were within normal range. Conclusions: RV GLS and RV FWLS PK reduction following ANT exposure is extremely frequent, comparing to LV GLS reduction.

Original language	English
Article number	291
Journal	Life
Volume	12
Issue number	2
DOIs	https://doi.org/10.3390/life12020291
State	Published - Feb 2022

Funding

Funders	Funder number
Israel Cardio-Oncology Registry
Pfizer pharmaceuticals Israel Ltd
Pfizer pharmaceuticals Israel Ltd.

Keywords

Anthracycline
Cardio-oncology
Cardiotoxicity
Right ventricle
Strain

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/life12020291

Cite this

@article{212064f095294aa88f23ac187dc2c7ce,

title = "Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy",

abstract = "Background: Anthracycline (ANT) is the most recognized therapy known to cause cardi-otoxicity, mainly left ventricle (LV) dysfunction. Global Longitudinal Strain (GLS) is the optimal tool for assessment of subclinical LV dysfunction. Right ventricle (RV) function has been recognized as an independent factor for cardiac outcomes; however, data evaluating RV GLS is limited. We aimed to evaluate the change in RV GLS following ANT therapy. Methods: The study cohort is part of the Israel Cardio-Oncology Registry (ICOR). All patients performed echocardiography before (T1) and at the end (T3) of ANT therapy. A significant reduction was defined as a relative reduction of ≥ 10% in RV GLS values. Results: The study included 40 female patients with breast cancer treated with ANT. During follow-up, both RV GLS and free wall longitudinal strain systolic peak (RV FWLS PK) decreased significantly (p < 0.001 and p = 0.002). Altogether, 30 (75%) and 23 (58%) patients showed RV GLS and RV FWLS PK ≥ 10% relative reduction. At T3, LV ejection fraction and LV GLS were within normal range. Conclusions: RV GLS and RV FWLS PK reduction following ANT exposure is extremely frequent, comparing to LV GLS reduction.",

keywords = "Anthracycline, Cardio-oncology, Cardiotoxicity, Right ventricle, Strain",

author = "Michal Laufer-Perl and Moran Perelman-Gvili and Dorfman, {Svetlana Sirota} and Guy Baruch and Ehud Rothschild and Gil Beer and Yaron Arbel and Arnold, {Joshua H.} and Zach Rozenbaum and Shmuel Banai and Yan Topilsky and Livia Kapusta",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

doi = "10.3390/life12020291",

language = "אנגלית",

volume = "12",

journal = "Life",

issn = "2075-1729",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy

AU - Laufer-Perl, Michal

AU - Perelman-Gvili, Moran

AU - Dorfman, Svetlana Sirota

AU - Baruch, Guy

AU - Rothschild, Ehud

AU - Beer, Gil

AU - Arbel, Yaron

AU - Arnold, Joshua H.

AU - Rozenbaum, Zach

AU - Banai, Shmuel

AU - Topilsky, Yan

AU - Kapusta, Livia

PY - 2022/2

Y1 - 2022/2

N2 - Background: Anthracycline (ANT) is the most recognized therapy known to cause cardi-otoxicity, mainly left ventricle (LV) dysfunction. Global Longitudinal Strain (GLS) is the optimal tool for assessment of subclinical LV dysfunction. Right ventricle (RV) function has been recognized as an independent factor for cardiac outcomes; however, data evaluating RV GLS is limited. We aimed to evaluate the change in RV GLS following ANT therapy. Methods: The study cohort is part of the Israel Cardio-Oncology Registry (ICOR). All patients performed echocardiography before (T1) and at the end (T3) of ANT therapy. A significant reduction was defined as a relative reduction of ≥ 10% in RV GLS values. Results: The study included 40 female patients with breast cancer treated with ANT. During follow-up, both RV GLS and free wall longitudinal strain systolic peak (RV FWLS PK) decreased significantly (p < 0.001 and p = 0.002). Altogether, 30 (75%) and 23 (58%) patients showed RV GLS and RV FWLS PK ≥ 10% relative reduction. At T3, LV ejection fraction and LV GLS were within normal range. Conclusions: RV GLS and RV FWLS PK reduction following ANT exposure is extremely frequent, comparing to LV GLS reduction.

AB - Background: Anthracycline (ANT) is the most recognized therapy known to cause cardi-otoxicity, mainly left ventricle (LV) dysfunction. Global Longitudinal Strain (GLS) is the optimal tool for assessment of subclinical LV dysfunction. Right ventricle (RV) function has been recognized as an independent factor for cardiac outcomes; however, data evaluating RV GLS is limited. We aimed to evaluate the change in RV GLS following ANT therapy. Methods: The study cohort is part of the Israel Cardio-Oncology Registry (ICOR). All patients performed echocardiography before (T1) and at the end (T3) of ANT therapy. A significant reduction was defined as a relative reduction of ≥ 10% in RV GLS values. Results: The study included 40 female patients with breast cancer treated with ANT. During follow-up, both RV GLS and free wall longitudinal strain systolic peak (RV FWLS PK) decreased significantly (p < 0.001 and p = 0.002). Altogether, 30 (75%) and 23 (58%) patients showed RV GLS and RV FWLS PK ≥ 10% relative reduction. At T3, LV ejection fraction and LV GLS were within normal range. Conclusions: RV GLS and RV FWLS PK reduction following ANT exposure is extremely frequent, comparing to LV GLS reduction.

KW - Anthracycline

KW - Cardio-oncology

KW - Cardiotoxicity

KW - Right ventricle

KW - Strain

UR - http://www.scopus.com/inward/record.url?scp=85124816519&partnerID=8YFLogxK

U2 - 10.3390/life12020291

DO - 10.3390/life12020291

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35207578

AN - SCOPUS:85124816519

SN - 2075-1729

VL - 12

JO - Life

JF - Life

IS - 2

M1 - 291

ER -

Prevalence of Right Ventricle Strain Changes following Anthracycline Therapy

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this